Put Options

9 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.54 - $0.86 $1,566 - $2,494
-2,900 Reduced 11.55%
22,200 $14,000
Q2 2024

Aug 14, 2024

SELL
$0.58 - $1.47 $28,361 - $71,883
-48,900 Reduced 66.08%
25,100 $14,000
Q1 2024

May 15, 2024

BUY
$0.72 - $1.46 $13,968 - $28,324
19,400 Added 35.53%
74,000 $102,000
Q4 2023

Feb 14, 2024

SELL
$0.61 - $0.99 $49,288 - $79,992
-80,800 Reduced 59.68%
54,600 $45,000
Q3 2023

Nov 14, 2023

SELL
$1.03 - $2.02 $50,058 - $98,172
-48,600 Reduced 26.41%
135,400 $147,000
Q2 2023

Aug 14, 2023

BUY
$0.82 - $2.49 $65,025 - $197,457
79,300 Added 75.74%
184,000 $356,000
Q1 2023

May 15, 2023

SELL
$0.8 - $1.22 $26,800 - $40,870
-33,500 Reduced 24.24%
104,700 $91,000
Q4 2022

Feb 14, 2023

BUY
$0.69 - $2.21 $32,705 - $104,754
47,400 Added 52.2%
138,200 $136,000
Q3 2022

Nov 14, 2022

BUY
$0.89 - $1.71 $52,154 - $100,206
58,600 Added 181.99%
90,800 $155,000

Others Institutions Holding XFOR

About X4 Pharmaceuticals, Inc


  • Ticker XFOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,646,096
  • Market Cap $26.8M
  • Description
  • X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...
More about XFOR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.